ArticleFEBS letters2006
Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus.
Article in FEBS letters, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 37 citations in OpenAlex.
- Therapeutic Approaches of Viral Gene Silencing by Small Interfering RNA: Strategies to Prevent the Emergence of Antiviral Resistant Escape Mutants.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.Signal transduction and targeted therapy · 2023Review
- From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis.Communications biology · 2023Article
- Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVID-19.IET nanobiotechnology · 2022Review
- Genome wide screen of RNAi molecules against SARS-CoV-2 creates a broadly potent prophylaxis.bioRxiv : the preprint server for biology · 2022Article
- Nucleic Acid-Based Technologies Targeting Coronaviruses.Trends in biochemical sciences · 2021Review
- SARS-CoV-2: phylogenetic origins, pathogenesis, modes of transmission, and the potential role of nanotechnology.Virusdisease · 2021Review
- Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs.Frontiers in microbiology · 2021Review
- Emerging Technologies for the Treatment of COVID-19.Advances in experimental medicine and biology · 2021Article
- Non-Coding RNAs and SARS-Related Coronaviruses.Viruses · 2020Review
- Therapeutic modalities and novel approaches in regenerative medicine for COVID-19.International journal of antimicrobial agents · 2020Review
- Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option.Annals of translational medicine · 2020Review
- Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger!Journal of cellular and molecular medicine · 2020Article
- Prospects for RNAi Therapy of COVID-19.Frontiers in bioengineering and biotechnology · 2020Review
- Article
- In vitro inhibition of feline coronavirus replication by small interfering RNAs.Veterinary microbiology · 2011Article
- Identification and characterization of three novel small interference RNAs that effectively down-regulate the isolated nucleocapsid gene expression of SARS coronavirus.Molecules (Basel, Switzerland) · 2011Article
- Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus.Molecular & cellular proteomics : MCP · 2009Article
- The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Nature reviews. Microbiology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-associated coronavirus was identified as the etiological agent of severe acute respiratory syndrome and a large virus pool was identified in wild animals. Virus generates drug resistance through fast mutagenesis and escapes antiviral treatment. siRNAs targeting different genes would be an alternative for overcoming drug resistance. Here, we report effective siRNAs targeting structural genes (i.e., spike, envelope, membrane, and nucleocapsid) and their antiviral kinetics. We also showed the synergistic effects of two siRNAs targeting different functional genes at a very low dose. Our findings may pave a way to develop cost effective siRNA agents for antiviral therapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.